Advertisement
American Journal of Kidney Diseases

Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis

Published:September 16, 2016DOI:https://doi.org/10.1053/j.ajkd.2016.07.024

      Background

      Percutaneous coronary intervention (PCI) use is low in the setting of stable symptomatic angina in individuals with advanced chronic kidney disease (CKD) despite high cardiovascular risk in this population, and PCI is frequently deferred out of concern for precipitating dialysis therapy. Whether this is appropriate is uncertain, and patient-centered data comparing the relative risks and benefits of continued medical therapy versus PCI in patients with advanced CKD and stable angina are scarce.

      Study Design

      Decision analysis.

      Setting & Population

      Hypothetical cohort of individuals with advanced CKD (stages 4-5 with estimated glomerular filtration rates ≤ 20 mL/min/1.73 m2) and stable angina.

      Model, Perspective, & Timeline

      A Markov model with a Monte Carlo simulation through 12 cycles, that is, 3 years of 3-month intervals, with 10,000 microsimulations predicted mean quality-adjusted life-years.

      Intervention

      PCI first, medical management, or dialysis (hemodialysis [HD]) followed by PCI.

      Outcomes

      Outcomes modeled were progression to HD therapy (for those not assigned to the preemptive HD strategy), catheter infection, and death.

      Results

      Our analysis showed mean quality-adjusted life-years of 1.103 ± 0.69 for PCI first, 1.088 ± 0.70 for medical management, and 0.670 ± 0.58 for HD followed by PCI. Probabilistic sensitivity analysis found PCI as the preferred strategy > 60% of the time.

      Limitations

      Values for probabilities and utilities were estimated and/or derived from multiple sources that were not uniform in their populations in terms of age, comorbid condition burden, and degree of kidney failure, and several simplifying assumptions were made.

      Conclusions

      Our analysis demonstrates that quality-adjusted life expectancy is similar for the PCI first and medical management strategies in patients with advanced CKD with stable angina and that the decision depends on patient preferences other than those incorporated in our model. Both strategies are superior to preemptive dialysis.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • McCulloch C.E.
        • Hsu C.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        • Marenzi G.
        • Cabiati A.
        • Assanelli E.
        Chronic kidney disease in acute coronary syndromes.
        World J Nephrol. 2012; 1: 134-145
        • Pucelikova T.
        • Dangas G.
        • Mehran R.
        Contrast-induced nephropathy.
        Cathet Cardiovasc Interv. 2008; 71: 62-72
        • Dangas G.
        • Iakovou I.
        • Nikolsky E.
        • et al.
        Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
        Am J Cardiol. 2005; 95: 13-19
        • Charytan D.M.
        • Wallentin L.
        • Lagerqvist B.
        • et al.
        Early angiography in patients with chronic kidney disease: a collaborative systematic review.
        Clin J Am Soc Nephrol. 2009; 4: 1032-1043
        • Marenzi G.
        • Lauri G.
        • Assanelli E.
        • et al.
        Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
        J Am Coll Cardiol. 2004; 44: 1780-1785
        • Chertow G.M.
        • Normand S.-L.T.
        • McNeil B.J.
        “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency.
        J Am Soc Nephrol. 2004; 15: 2462-2468
        • Charytan D.
        • Mauri L.
        • Agarwal A.
        • Servoss S.
        • Scirica B.
        • Kuntz R.E.
        The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients.
        Am Heart J. 2006; 152: 558-564
        • Sedlis S.P.
        • Jurkovitz C.T.
        • Hartigan P.M.
        • et al.
        Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.
        Am J Cardiol. 2009; 104: 1647-1653
        • Wijeysundera H.C.
        • Nallamothu B.K.
        • Krumholz H.M.
        • Tu J.V.
        • Ko D.T.
        Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief.
        Ann Intern Med. 2010; 152: 370-379
        • Gupta T.
        • Paul N.
        • Kolte D.
        • et al.
        Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention.
        J Am Heart Assoc. 2015; 4: e002069
        • Saran R.
        • Li Y.
        • Robinson B.
        • et al.
        US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2015; 66: S1-S306
        • Anderson S.
        • Halter J.B.
        • Hazzard W.R.
        • et al.
        Prediction, progression, and outcomes of chronic kidney disease in older adults.
        J Am Soc Nephrol. 2009; 20: 1199-1209
        • Landray M.J.
        • Emberson J.R.
        • Blackwell L.
        • et al.
        Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.
        Am J Kidney Dis. 2010; 56: 1082-1094
        • Hallan S.I.
        • Matsushita K.
        • Sang Y.
        • et al.
        Age and association of kidney measures with mortality and end-stage renal disease.
        JAMA. 2012; 308: 2349-2360
        • Birck R.
        • Krzossok S.
        • Markowetz F.
        • Schnülle P.
        • van der Woude F.J.
        • Braun C.
        Acetylcysteine for prevention of contrast nephropathy: meta-analysis.
        Lancet. 2003; 362: 598-603
        • Rudnick M.
        • Feldman H.
        Contrast-induced nephropathy: what are the true clinical consequences?.
        Clin J Am Soc Nephrol. 2008; 3: 263-272
        • Mehran R.
        • Nikolsky E.
        Contrast-induced nephropathy: definition, epidemiology, and patients at risk.
        Kidney Int Suppl. 2006; 100: S11-S15
        • Neyra J.A.
        • Shah S.
        • Mooney R.
        • Jacobsen G.
        • Yee J.
        • Novak J.E.
        Contrast-induced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease.
        Nephrol Dial Transplant. 2013; 28: 1463-1471
        • Rihal C.S.
        Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.
        Circulation. 2002; 105: 2259-2264
        • Slocum N.K.
        • Grossman P.M.
        • Moscucci M.
        • et al.
        The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
        Am Heart J. 2012; 163: 829-834
        • Lee T.
        • Barker J.
        • Allon M.
        Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes.
        Am J Kidney Dis. 2005; 46: 501-508
        • Schild A.F.
        • Perez E.
        • Gillaspie E.
        • Seaver C.
        • Livingstone J.
        • Thibonnier A.
        Arteriovenous fistulae vs. arteriovenous grafts: a retrospective review of 1,700 consecutive vascular access cases.
        J Vasc Access. 2008; 9: 231-235
        • Ravani P.
        • Palmer S.C.
        • Oliver M.J.
        • et al.
        Associations between hemodialysis access type and clinical outcomes: a systematic review.
        J Am Soc Nephrol. 2013; 24: 465-473
        • Ladapo J.A.
        • Hoffmann U.
        • Bamberg F.
        • et al.
        Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain.
        AJR Am J Roentgenol. 2008; 191: 455-463
        • Lalonde L.
        • Clarke A.E.
        • Joseph L.
        • Mackenzie T.
        • Grover S.A.
        Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group.
        Qual Life Res. 1999; 8: 399-409
        • Gorodetskaya I.
        • Zenios S.
        • McCulloch C.E.
        • et al.
        Health-related quality of life and estimates of utility in chronic kidney disease.
        Kidney Int. 2005; 68: 2801-2808
        • Davison S.N.
        • Jhangri G.S.
        • Feeny D.H.
        Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 preference-based SF-6D in chronic kidney disease.
        Value Health. 2009; 12: 340-345
        • Hiremath S.
        • Knoll G.
        • Weinstein M.C.
        Should the arteriovenous fistula be created before starting dialysis? A decision analytic approach.
        PloS One. 2011; 6: e28453
        • Claxton K.
        The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.
        J Health Econ. 1999; 18: 341-364
        • Claxton K.
        • Sculpher M.
        • McCabe C.
        • et al.
        Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
        Health Econ. 2005; 14: 339-347
        • Pursnani S.
        • Korley F.
        • Gopaul R.
        • et al.
        Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.
        Circ Cardiovasc Interv. 2012; 5: 476-490
        • Sedlis S.P.
        • Jurkovitz C.T.
        • Hartigan P.M.
        • et al.
        Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).
        Am J Cardiol. 2013; 112: 1703-1708
        • Berger A.K.
        • Duval S.
        • Krumholz H.M.
        Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
        J Am Coll Cardiol. 2003; 42: 201-208
        • Hung Y.-M.
        • Lin S.-L.
        • Hung S.-Y.
        • Huang W.-C.
        • Wang P.Y.-P.
        Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.
        World J Cardiol. 2012; 4: 157-172
        • Boden W.E.
        • O’Rourke R.A.
        • Teo K.K.
        • et al.
        Optimal medical therapy with or without PCI for stable coronary disease.
        N Engl J Med. 2007; 356: 1503-1516
        • Kassirer J.P.
        • Pauker S.G.
        The toss-up.
        N Engl J Med. 1981; 305: 1467-1469